-
ChloraPrep 2% w/v 70% v/v Cutaneous Solution, 1 ml Applicators and Frepp™ 1.5 ml Applicators, PA2287/001/002, batch recall
May 26, 2026, 11:13 -
Tyvense Capsules, hard - Introduction of a New Contraindication - Pheochromocytoma
May 22, 2026, 12:00 -
MiniMed™ Paradigm™, MiniMed™ 600 series, and MiniMed™ 700 series insulin pump systems Priority 2 - Warning
May 18, 2026, 11:59 -
Cosmetic Safety Gate alerts impacting the Irish market - March 2026
May 15, 2026, 10:23 -
Ontozry (cenobamate): new requirements for liver monitoring due to reports of severe liver injury
May 12, 2026, 00:00 -
Tecovirimat SIGA – Indication restricted following lack of efficacy in mpox trials
May 11, 2026, 08:49 -
PRAC meeting highlights 04 - 07 May 2026
May 8, 2026, 13:40 -
Summary of Field Safety Notices April 2026
May 5, 2026, 17:27 -
Cosmetic Safety Gate alerts impacting the Irish market - April 2026
Apr 13, 2026, 10:58 -
PRAC meeting highlights 07 - 10 April 2026
Apr 10, 2026, 15:56 -
HPRA Drug Safety Newsletter – Issue 122 – 8 April 2026
Apr 8, 2026, 14:04 -
Summary of Field Safety Notices March 2026
Apr 7, 2026, 15:55 -
Omnipaque 350 mg I/ml Solution for Injection and Visipaque 320 mg l/ml Solution for Injection - Batch Recall
Mar 23, 2026, 11:44 -
PRAC meeting highlights 09 - 12 March 2026
Mar 13, 2026, 16:35 -
Cosmetic Safety Gate alerts impacting the Irish market - February 2026
Mar 11, 2026, 15:14 -
Ventolin Evohaler 100 micrograms pressurised inhalation contains enough medicine for 200 puffs only
Mar 10, 2026, 15:29 -
Summary of Field Safety Notices February 2026
Mar 4, 2026, 14:01 -
Noradrenaline, Mykronor 5 μg/mL, solution for injection/infusion - potential risk of medication errors
Feb 20, 2026, 14:53 -
Remsima (infliximab): New IV formulation (100 mg and 350 mg concentrate for solution for infusion) contains sorbitol and is therefore contraindicated in patients with hereditary fructose intolerance
Feb 17, 2026, 09:56 -
PRAC meeting highlights 09 - 12 February 2026
Feb 13, 2026, 15:00
